Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread within the human population. Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the coronavirus disease...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cell Ročník 184; číslo 7; s. 1858
Hlavní autoři: Anderson, Elizabeth M, Goodwin, Eileen C, Verma, Anurag, Arevalo, Claudia P, Bolton, Marcus J, Weirick, Madison E, Gouma, Sigrid, McAllister, Christopher M, Christensen, Shannon R, Weaver, JoEllen, Hicks, Philip, Manzoni, Tomaz B, Oniyide, Oluwatosin, Ramage, Holly, Mathew, Divij, Baxter, Amy E, Oldridge, Derek A, Greenplate, Allison R, Wu, Jennifer E, Alanio, Cécile, D'Andrea, Kurt, Kuthuru, Oliva, Dougherty, Jeanette, Pattekar, Ajinkya, Kim, Justin, Han, Nicholas, Apostolidis, Sokratis A, Huang, Alex C, Vella, Laura A, Kuri-Cervantes, Leticia, Pampena, M Betina, Betts, Michael R, Wherry, E John, Meyer, Nuala J, Cherry, Sara, Bates, Paul, Rader, Daniel J, Hensley, Scott E
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.04.2021
Témata:
ISSN:1097-4172, 1097-4172
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly spread within the human population. Although SARS-CoV-2 is a novel coronavirus, most humans had been previously exposed to other antigenically distinct common seasonal human coronaviruses (hCoVs) before the coronavirus disease 2019 (COVID-19) pandemic. Here, we quantified levels of SARS-CoV-2-reactive antibodies and hCoV-reactive antibodies in serum samples collected from 431 humans before the COVID-19 pandemic. We then quantified pre-pandemic antibody levels in serum from a separate cohort of 251 individuals who became PCR-confirmed infected with SARS-CoV-2. Finally, we longitudinally measured hCoV and SARS-CoV-2 antibodies in the serum of hospitalized COVID-19 patients. Our studies indicate that most individuals possessed hCoV-reactive antibodies before the COVID-19 pandemic. We determined that ∼20% of these individuals possessed non-neutralizing antibodies that cross-reacted with SARS-CoV-2 spike and nucleocapsid proteins. These antibodies were not associated with protection against SARS-CoV-2 infections or hospitalizations, but they were boosted upon SARS-CoV-2 infection.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1097-4172
1097-4172
DOI:10.1016/j.cell.2021.02.010